Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Balbino B, Herviou P, Godon O, Stackowicz J, Goff OR, Iannascoli B, Sterlin D, Brûlé S, Millot GA, Harris FM, Voronina VA, Nadeau KC, Macdonald LE, Murphy AJ, Bruhns P, Reber LL.

J Clin Invest. 2020 Jan 27. pii: 129697. doi: 10.1172/JCI129697. [Epub ahead of print]

2.

LGP2 binds to PACT to regulate RIG-I- and MDA5-mediated antiviral responses.

Sanchez David RY, Combredet C, Najburg V, Millot GA, Beauclair G, Schwikowski B, Léger T, Camadro JM, Jacob Y, Bellalou J, Jouvenet N, Tangy F, Komarova AV.

Sci Signal. 2019 Oct 1;12(601). pii: eaar3993. doi: 10.1126/scisignal.aar3993.

PMID:
31575732
3.

Transcription-dependent regulation of replication dynamics modulates genome stability.

Blin M, Le Tallec B, Nähse V, Schmidt M, Brossas C, Millot GA, Prioleau MN, Debatisse M.

Nat Struct Mol Biol. 2019 Jan;26(1):58-66. doi: 10.1038/s41594-018-0170-1. Epub 2018 Dec 31.

PMID:
30598553
4.

The Loss of Expression of a Single Type 3 Effector (CT622) Strongly Reduces Chlamydia trachomatis Infectivity and Growth.

Cossé MM, Barta ML, Fisher DJ, Oesterlin LK, Niragire B, Perrinet S, Millot GA, Hefty PS, Subtil A.

Front Cell Infect Microbiol. 2018 May 15;8:145. doi: 10.3389/fcimb.2018.00145. eCollection 2018.

5.

Heritability of the melatonin synthesis variability in autism spectrum disorders.

Benabou M, Rolland T, Leblond CS, Millot GA, Huguet G, Delorme R, Leboyer M, Pagan C, Callebert J, Maronde E, Bourgeron T.

Sci Rep. 2017 Dec 18;7(1):17746. doi: 10.1038/s41598-017-18016-3.

6.

Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Golmard L, Castéra L, Krieger S, Moncoutier V, Abidallah K, Tenreiro H, Laugé A, Tarabeux J, Millot GA, Nicolas A, Laé M, Abadie C, Berthet P, Polycarpe F, Frébourg T, Elan C, de Pauw A, Gauthier-Villars M, Buecher B, Stern MH, Stoppa-Lyonnet D, Vaur D, Houdayer C.

Eur J Hum Genet. 2017 Dec;25(12):1345-1353. doi: 10.1038/s41431-017-0021-2. Epub 2017 Nov 8.

7.

Mosaicism and prenatal diagnosis options: insights from retinoblastoma.

Dehainault C, Golmard L, Millot GA, Charpin A, Laugé A, Tarabeux J, Aerts I, Cassoux N, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C.

Eur J Hum Genet. 2017 Feb;25(3):381-383. doi: 10.1038/ejhg.2016.174. Epub 2016 Dec 21.

8.

Yeast cells reveal the misfolding and the cellular mislocalization of the human BRCA1 protein.

Thouvenot P, Fourrière L, Dardillac E, Ben Yamin B, Lescure A, Lejour V, Heiligenstein X, Boulé JB, Romao M, Raposo-Benedetti G, Lopez BS, Nicolas A, Millot GA.

J Cell Sci. 2016 Dec 1;129(23):4366-4378. Epub 2016 Oct 17.

9.

Single-molecule, antibody-free fluorescent visualisation of replication tracts along barcoded DNA molecules.

De Carli F, Gaggioli V, Millot GA, Hyrien O.

Int J Dev Biol. 2016;60(7-8-9):297-304.

10.

Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making.

Thouvenot P, Ben Yamin B, Fourrière L, Lescure A, Boudier T, Del Nery E, Chauchereau A, Goldgar DE, Houdayer C, Stoppa-Lyonnet D, Nicolas A, Millot GA.

PLoS Genet. 2016 Jun 6;12(6):e1006096. doi: 10.1371/journal.pgen.1006096. eCollection 2016 Jun.

11.

A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1.

Eloy P, Dehainault C, Sefta M, Aerts I, Doz F, Cassoux N, Lumbroso le Rouic L, Stoppa-Lyonnet D, Radvanyi F, Millot GA, Gauthier-Villars M, Houdayer C.

PLoS Genet. 2016 Feb 29;12(2):e1005888. doi: 10.1371/journal.pgen.1005888. eCollection 2016 Feb.

12.

Signaling from Mus81-Eme2-Dependent DNA Damage Elicited by Chk1 Deficiency Modulates Replication Fork Speed and Origin Usage.

Técher H, Koundrioukoff S, Carignon S, Wilhelm T, Millot GA, Lopez BS, Brison O, Debatisse M.

Cell Rep. 2016 Feb 9;14(5):1114-1127. doi: 10.1016/j.celrep.2015.12.093. Epub 2016 Jan 21.

13.

BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

Jhuraney A, Velkova A, Johnson RC, Kessing B, Carvalho RS, Whiley P, Spurdle AB, Vreeswijk MP, Caputo SM, Millot GA, Vega A, Coquelle N, Galli A, Eccles D, Blok MJ, Pal T, van der Luijt RB, Santamariña Pena M, Neuhausen SL, Donenberg T, Machackova E, Thomas S, Vallée M, Couch FJ, Tavtigian SV, Glover JN, Carvalho MA, Brody LC, Sharan SK, Monteiro AN; Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium.

J Med Genet. 2015 Apr;52(4):224-30. doi: 10.1136/jmedgenet-2014-102766. Epub 2015 Feb 2.

14.

Common fragile site profiling in epithelial and erythroid cells reveals that most recurrent cancer deletions lie in fragile sites hosting large genes.

Le Tallec B, Millot GA, Blin ME, Brison O, Dutrillaux B, Debatisse M.

Cell Rep. 2013 Aug 15;4(3):420-8. doi: 10.1016/j.celrep.2013.07.003. Epub 2013 Aug 1.

15.

A guide for functional analysis of BRCA1 variants of uncertain significance.

Millot GA, Carvalho MA, Caputo SM, Vreeswijk MP, Brown MA, Webb M, Rouleau E, Neuhausen SL, Hansen Tv, Galli A, Brandão RD, Blok MJ, Velkova A, Couch FJ, Monteiro AN; ENIGMA Consortium Functional Assay Working Group.

Hum Mutat. 2012 Nov;33(11):1526-37. doi: 10.1002/humu.22150. Epub 2012 Jul 16. Review.

16.

Molecular profiling of common fragile sites in human fibroblasts.

Le Tallec B, Dutrillaux B, Lachages AM, Millot GA, Brison O, Debatisse M.

Nat Struct Mol Biol. 2011 Nov 6;18(12):1421-3. doi: 10.1038/nsmb.2155.

PMID:
22056772
17.

Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.

Millot GA, Berger A, Lejour V, Boulé JB, Bobo C, Cullin C, Lopes J, Stoppa-Lyonnet D, Nicolas A.

Hum Mutat. 2011 Dec;32(12):1470-80. doi: 10.1002/humu.21608. Epub 2011 Oct 20.

PMID:
21922593
18.

Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site.

Letessier A, Millot GA, Koundrioukoff S, Lachagès AM, Vogt N, Hansen RS, Malfoy B, Brison O, Debatisse M.

Nature. 2011 Feb 3;470(7332):120-3. doi: 10.1038/nature09745. Epub 2011 Jan 23.

PMID:
21258320
19.

Nucleotide supply, not local histone acetylation, sets replication origin usage in transcribed regions.

Gay S, Lachages AM, Millot GA, Courbet S, Letessier A, Debatisse M, Brison O.

EMBO Rep. 2010 Sep;11(9):698-704. doi: 10.1038/embor.2010.112. Epub 2010 Jul 30.

20.

Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.

Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P; Réseau d'Etude des Microangiopathies Thrombotiques (TMA-Rare Diseases Reference Center).

Scand J Immunol. 2008 Sep;68(3):337-44. doi: 10.1111/j.1365-3083.2008.02143.x.

21.

Proteome analysis of differentiating human myoblasts by dialysis-assisted two-dimensional gel electrophoresis (DAGE).

Gonnet F, Bouazza B, Millot GA, Ziaei S, Garcia L, Butler-Browne GS, Mouly V, Tortajada J, Danos O, Svinartchouk F.

Proteomics. 2008 Jan;8(2):264-78. doi: 10.1002/pmic.200700261.

PMID:
18203276
22.

Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.

Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.

Br J Haematol. 2006 Jan;132(1):66-74. Review.

PMID:
16371021
23.

Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.

Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Frémeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.

Medicine (Baltimore). 2004 Jul;83(4):233-44.

24.

Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies.

Millot GA, Vainchenker W, Duménil D, Svinarchuk F.

Cell Signal. 2004 Mar;16(3):355-63.

PMID:
14687665
25.

Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells.

Millot GA, Vainchenker W, Duménil D, Svinarchuk F.

J Cell Sci. 2002 Jun 1;115(Pt 11):2329-37.

26.

Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro.

Filippi MD, Porteu F, Le Pesteur F, Schiavon V, Millot GA, Vainchenker W, de Sauvage FJ, Dubart Kupperschmitt A, Sainteny F.

Blood. 2002 Feb 15;99(4):1174-82.

PMID:
11830463
27.
28.

The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5.

Millot GA, Svinarchuk F, Lacout C, Vainchenker W, Dumenil D.

Br J Haematol. 2001 Feb;112(2):449-58.

PMID:
11167846

Supplemental Content

Loading ...
Support Center